Daniel Carrizosa is an Oncology physician affiliated with Levine Cancer Institute. OpenAlex indexes 87 publications with 955 citations (h-index 14); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
15830 Ballantyne Medical Pl
Ste 200
Charlotte, NC 282774653
Telephone
980-442-9600Provider last certified this registry record 7 Apr 2022.
Clinical trials
- Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
Sponsor: Wake Forest University Health Sciences
- Breast Health Education for Underserved Latino Women
Sponsor: Wake Forest University Health Sciences
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20254 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20253 payments
- Merck Sharp & Dohme LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
34.3%Atypical Antipsychotic8.4%Olanzapine100%Part D<11 patientsOpioid Agonist7.9%Oxycodone Hcl100%Part D<11 patients+ 3 more classes in this area
Cancer & immunology
23.8%Kinase inhibitor18%Tagrisso44%Gleevec28%Jakafi28%Part D<11 patientsAromatase Inhibitor5.9%Anastrozole100%Part D<11 patientsMetabolism & gastrointestinal
20.5%Serotonin-3 Receptor Antagonist13.8%Ondansetron Odt52%Ondansetron Hcl49%Part D<11 patientsProton pump inhibitor6.7%Omeprazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Peter Voorhees, MD
Levine Cancer Institute
Edward Copelan, MD
Levine Cancer Institute
Nilanjan Ghosh, MD
Levine Cancer Institute
Antoinette Tan, MD
Levine Cancer Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”